TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07279935: Biomarker-Directed Treatment in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC: A Prospective, Multi-cohort, Interventional Study (REVIVE)

Sponsor: AstraZeneca · Phase: PHASE4 · Area: ONCOLOGY · Target Enrollment: 100 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$443,520

Rescue Site Savings

+$295,680

Unlock Full NCT07279935 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07279935 Rescue Dossier →